Cyllene Therapeutics expanded its leadership team, appointing a new board member and two VPs, to support corporate growth.
Cyllene Therapeutics is a French biotechnology company pioneering pinpoint gene therapy using a non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform to develop DNA medicines for chronic diseases, particularly targeting peripheral nervous system disorders
Cyllene Therapeutics is a French biotechnology company pioneering pinpoint gene therapy using a non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform to develop DNA medicines for chronic diseases, particularly targeting peripheral nervous system disorders.